iOnctura

🗞 Breaking News! 🗞 We are thrilled to announce we have successfully closed our 80M Euro Series B financing round. 📣 Led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council (EIC), as well as existing investors M Ventures , Inkef Capital, Vi Partners, Schroders Capital and 3B Future Health Fund I & II, this funding highlights a shared vision for the potential of our portfolio of precision oral small molecules.   This significant funding will:   🚀 Accelerate development of #roginolisib for the treatment of #uvealmelanoma through a randomized Phase II study 🚀 Broaden development of roginolisib for other cancer indications, including randomized Phase II studies in #NSCLC and primary #myelofibrosis 🚀 Progress #cambritaxestat and IOA-359 programs   Watch this space as we kick off a number of Phase II studies later in 2024.   Thank you to the team, investors and collaborators who continue to support and drive iOnctura forward. Link to press release in comments ⬇ #financing #oncology #drugdevelopment

In this week's Meet Our Team series we introduce... 🌟 SVP New Product Planning & Business Transformation Paul Beresford 🌟 A seasoned veteran in oncology rare disease product launches, Paul joins the iOnctura team to guide our strategy as we bring our clinical products towards the market. Getting drugs into the hands of patients requires more than just good data. With Paul's guidance we are preparing to meet the needs of payors and health technology assessment organisations as well as building our company to optimize future product launches. When not planning product launches, Paul can be found on rugby pitches across Switzerland, planning strategies to lead the teams he coaches to victory 🏉 #meettheteam #teamworkmakesthedreamwork

Are you at #ENA2024 today? If so, we invite you to pop by Chiara Tarantelli's poster from the laboratory of our collaborator Francesco Bertoni this afternoon. By using genome-wide genetic screening, Chiara's work identifed genes modulating lymphoma cells’ response to our allosteric modulator of PI3Kδ #roginolisib. She further identified potential biomarkers of response and highlighted potential combination partners to be explored further.

💡 NEW RESEARCH PUBLISHED 💡 We are thrilled to annouce today the peer-reviewed publication of research results supporting the potential of autotaxin-targeted drugs, such as our #cambritaxestat, in #gastric cancer. The research showed that ENPP2 mutations (the gene that makes the enzyme autotaxin) were associated with poor overall survival in gastric cancer and circulating autotaxin levels were associated with an increased risk of death. Given these findings, autotaxin inhibitors may be useful for combining with standard regimes in appropriately selected gastric cancer patients. Full article can be downloaded from our website here: 👉 https://lnkd.in/eJWN6cW3 #oncology #drugdiscovery

Galloping into Monday we bring you another "Meet the Team" series introducing.... 🌟Director of Clinical Development and Operations Karen Tonge 🌟 Karen may be new to the iOnctura team but she's very far from new to clinical development and operations, bringing several decades of experience across large pharma and CROs to the team. We are so thankful to have her join us to manage our growing portfolio of clinical trials and programmes. Aside from iOnctura, Karen is a speed demon who loves nothing more than racing in the British Hill and Sprint Championships (for those not in the know, that means driving small cars at very big speeds) 🏎️. If she feels the need to slow down slightly she also loves trading in her car for a spot of horse riding 🐎 A very talented individual who we are very lucky to have on board. #meettheteam #teamworkmakesthedreamwork

Our mission is to develop high impact, low disruption therapies that extend healthspan for patients with uveal melanoma. We are so pleased to be in Scottsdale Arizona today and tomorrow to join the A Cure In Sight™'s 2024 Eye Believe Survivorship Seminar. Our CMO Michael L. will be listening to physicians and survivors, expanding his network and bringing back his insights to the iOnctura team. Uveal melanoma patients are at the heart of our mission and we are so glad to be attending this valuable meeting.

We had a blast last night at the Digital Impact Awards in London and were thrilled to receive not one but two awards for our new brand and website. A huge thank you to the talented Paul Alexander and Peter Furlong who supported us on this creative journey and who entered us for the award. three thirty studio are an amazing agency to work with; we couldn’t have done it without you!

Today, at 4pm CET, iOnctura's VP of Clinical Sciences, Paramjit Kaur, will be participating in a panel moderated by Fierce Biotech and Clarivate: Innovative Therapeutics: Challenges and Opportunities in Developing Drug Combinations If you would like to listen into the webinar and gain insights from leading experts, including Paramjit, on the latest advancements in combination pharmacology and clinical trial design then register here: 👉 https://lnkd.in/eYw3JbmA

How can European biotechs navigate everchanging capital markets? Our CEO Catherine Pickering chaired a panel on this topic yesterday discussing strategies from a private and public market perspective and pulling in the iOnctura viewpoint from our recent series B financing. Thank you Optimum Strategic Communications for a fantastic day of sharing experience, perspectives and positivity for the future.

We may have differing views on the UK's various political parties but can we all agree Rishi Sunak should be applauded for his public display of support this week for #ocularmelanoma Here he is packing boxes with books to help British charity Wendy's Wish who sell salvaged books to help research into this disease, which currently has limited therapeutic options. iOnctura's PI3Kd inhibitor roginoslib continues to show promising clinical activity and excellent safety for long periods of treatment in uveal melanoma